Side-Chain Modified Ergosterol and Stigmasterol Derivatives as Liver X Receptor Agonists

M Marinozzi, FF Castro Navas, Daniela Maggioni, E Carosati, G Bocci, M Carloncelli, G. Giorgi, Gabriele Cruciani, R Fontana, V Russo

Research output: Contribution to journalArticlepeer-review


A series of stigmasterol and ergosterol derivatives, characterized by the presence of oxygenated functions at C-22 and/or C-23 positions, were designed as potential liver X receptor (LXR) agonists. The absolute configuration of the newly created chiral centers was definitively assigned for all the corresponding compounds. Among the 16 synthesized compounds, 21, 27, and 28 were found to be selective LXRα agonists, whereas 20, 22, and 25 showed good selectivity for the LXRβ isoform. In particular, 25 showed the same degree of potency as 22R-HC (3) at LXRβ, while it was virtually inactive at LXRα (EC 50 = 14.51 μM). Interestingly, 13, 19, 20, and 25 showed to be LXR target gene-selective modulators, by strongly inducing the expression of ABCA1, while poorly or not activating the lipogenic genes SREBP1 and SCD1 or FASN, respectively. © 2017 American Chemical Society.
Original languageEnglish
Pages (from-to)6548-6562
Number of pages15
JournalJournal of Medicinal Chemistry
Issue number15
Publication statusPublished - 2017


Dive into the research topics of 'Side-Chain Modified Ergosterol and Stigmasterol Derivatives as Liver X Receptor Agonists'. Together they form a unique fingerprint.

Cite this